OptimizeRx Corp. (OPRX) Cash Flow Statement

The conversion ratio is distorted by near-zero or negative net income in several periods, so the sign-flipping values reflect denominator instability more than operating strength. Operating cash flow was positive in most quarters while net income was negative in six of ten, which suggests non-cash charges and working capital timing are driving much of the gap. Investors should monitor whether cash generation persists once net income turns consistently positive, as the current pattern warrants further investigation rather than confirming earnings quality.

Capital expenditure is negligible, with CapEx below 0.5% of revenue in every period, so free cash flow essentially equals operating cash flow and is highly sensitive to working capital movements. The Q2 2026 spike to $8.6M of free cash flow appears more consistent with timing benefits than with sustainable earnings power, given the preceding quarter was negative. A trailing view across the full ten quarters is the more reliable reading for analysts assessing run-rate cash generation.

Because working capital changes are of comparable or greater size than operating cash flow itself, the reported cash generation is heavily influenced by receivable collection and payable timing. The pattern of large outflows followed by inflows suggests the company's cash figures may be sensitive to period-end timing effects. Investors should monitor whether these swings reverse over time, as a persistent drag would indicate weaker underlying conversion than the headline numbers imply.

Stock-based compensation accounts for a material share of the difference between reported earnings and operating cash flow, meaning part of the apparent cash strength reflects non-cash equity expense rather than economic cash surplus. Net income was negative across most of the period, so the cumulative comparison is directionally favorable to cash but flattered by add-backs. Analysts should weigh this against the dilution cost of equity compensation when judging true cash returns to shareholders.